Patents by Inventor Frank W. Marcoux

Frank W. Marcoux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STRUCTURE, MANUFACTURING AND USES OF HUMAN-DERIVED CELL-PERMEABLE PEPTIDES CONJUGATED WITH SPECIFIC BIOLOGICALLY ACTIVE CARGO PEPTIDES
    Publication number: 20210180069
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 17, 2021
    Applicant: PPL (BVI) Limited
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
    Patent number: 10947539
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: March 16, 2021
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
    Patent number: 10301629
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: May 28, 2019
    Assignee: PORTAGE PHARMACEUTICALS LTD.
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • STRUCTURE, MANUFACTURING AND USES OF HUMAN-DERIVED CELL-PERMEABLE PEPTIDES CONJUGATED WITH SPECIFIC BIOLOGICALLY ACTIVE CARGO PEPTIDES
    Publication number: 20190153450
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Application
    Filed: February 6, 2019
    Publication date: May 23, 2019
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • STRUCTURE, MANUFACTURING AND USES OF HUMAN-DERIVED CELL-PERMEABLE PEPTIDES CONJUGATED WITH SPECIFIC BIOLOGICALLY ACTIVE CARGO PEPTIDES
    Publication number: 20160136293
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 19, 2016
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Method for using ketamine for prevention or reduction of the effects of stroke in a subject having increased risk for stroke
    Patent number: 5232950
    Abstract: The present invention is a method of use for the prevention or reduction of the effects of stroke in a subject susceptible to or at risk of stroke with ketamine. The method also includes combination of ketamine and a benzodiazepine in the use.
    Type: Grant
    Filed: January 5, 1990
    Date of Patent: August 3, 1993
    Assignee: Warner-Lambert Company
    Inventor: Frank W. Marcoux
  • Method for using diltiazem for treating stroke
    Patent number: 4696924
    Abstract: The present invention is a method of use for the treatment of stroke with one of diltiazem, verapamil, or nifedipine.
    Type: Grant
    Filed: August 6, 1986
    Date of Patent: September 29, 1987
    Assignee: Warner-Lambert Company
    Inventor: Frank W. Marcoux
  • Method for using nifedipine for treating stroke
    Patent number: 4696934
    Abstract: The present invention is a method of use for the treatment of stroke with one of diltiazem, verapamil, or nifedipine.
    Type: Grant
    Filed: August 6, 1986
    Date of Patent: September 29, 1987
    Assignee: Warner-Lambert Company
    Inventor: Frank W. Marcoux
  • Method for using verapamil for treating stroke
    Patent number: 4654372
    Abstract: The present invention is a method of use for the treatment of stroke with one of diltiazem, verapamil, or nifedipine.
    Type: Grant
    Filed: January 10, 1986
    Date of Patent: March 31, 1987
    Assignee: Warner-Lambert Company
    Inventor: Frank W. Marcoux